This was investigated in pediatric low grade astrocytoma and ependymoma cell lines treated with receptor tyrosine kinase (RTK) inhibitors e. g. sorafenib, dasatinib, canertinib and crizotinib. This evidence concerns the gene NTRK1 and astrocytoma (excluding glioblastoma).